Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Bioadaptives (BDPT) EPS (Basic) (2019 - 2025)

Bioadaptives' EPS (Basic) history spans 6 years, with the latest figure at -$0.05 for Q4 2024.

  • For Q4 2024, EPS (Basic) rose 59.39% year-over-year to -$0.05; the TTM value through Dec 2024 reached -$0.05, up 67.51%, while the annual FY2024 figure was -$0.11, 8.33% up from the prior year.
  • EPS (Basic) for Q4 2024 was -$0.05 at Bioadaptives, down from -$0.0 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.0 in Q3 2024 and bottomed at -$0.12 in Q4 2023.
  • The 5-year median for EPS (Basic) is -$0.0 (2022), against an average of -$0.01.
  • The largest YoY upside for EPS (Basic) was 96.17% in 2023 against a maximum downside of 10786.83% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.01 in 2020, then skyrocketed by 73.45% to -$0.0 in 2021, then surged by 58.49% to -$0.0 in 2022, then crashed by 10786.83% to -$0.12 in 2023, then surged by 59.39% to -$0.05 in 2024.
  • Per Business Quant, the three most recent readings for BDPT's EPS (Basic) are -$0.05 (Q4 2024), -$0.0 (Q3 2024), and -$0.0 (Q2 2024).